Bumetanide
Indications
Bumetanide is used for:
Hypertension, Heart failure, Oedema, Nephrotic syndrome
Adult Dose
Oral
Oedema
Adult: 1 mg once daily. Give 2nd dose 6-8 hr later if necessary.
Elderly: 0.5 mg daily.
Refractory oedema
Adult: Initially, 5 mg daily increased by 5 mg every 12-24 hr as required. High doses may be divided in 2-3 doses. Max: 10 mg/day.
Hypertension
Adult: 0.5-1 mg daily. Max: 5 mg/day.
Parenteral
Emergency cases of oedema
Adult: 0.5-1 mg via slow IV/IM inj, subsequently adjust dose according to response.
Intravenous
Pulmonary oedema
Adult: 1-2 mg IV repeated 20 min later if necessary, or 2-5 mg in 500 ml of a suitable infusion fluid given over 30-60 min.
Child Dose
Renal Dose
Administration
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Contra Indications
Hypersensitivity, progressive renal failure and anuria, hepatic coma, severe electrolyte depletion.
Precautions
Pregnancy, lactation; regular monitoring of serum electrolytes (especially potassium, calcium, magnesium); in case of hypokalemia, potassium supplements/potassium-sparing diuretics added. Monitor blood-glucose, BUN, creatinine levels as well as blood counts. Sulfonamide allergy. CHF patients on digitalis, K losing nephropathy, hepatic cirrhosis and ascitis, diarrhoeal states.
Lactation: Unknown whether drug is excreted in breast milk; use with caution
Pregnancy-Lactation
Pregnancy category: C
Lactation: Unknown whether drug is excreted in breast milk; use with caution
Interactions
Reduced diuretic and natriuretic actions by probenecid. Indometacin blunts action of bumetanide; concurrent usage with antihypertensives may increase risk of orthostatic hypotension.
Potentially Fatal: Avoid concurrent usage with ototoxic drugs such as aminoglycoides and nephrotoxic drugs. Reduced lithium excretion via kidneys.
Adverse Effects
Side effects of Bumetanide :
>10%
Hyperuricemia (18%), Hypochloremia (15%), Hypokalemia (15%), Azotemia (11%)
1-10%
Hyponatremia (9%), Hyperglycemia (7%), Increased serum creatinine (7%), Variations in phosphorus (5%), Variations in CO2 content (4%), Variations in bicarbonate (3%), Variations in calcium (2%), Dizziness (1%), Muscle cramps (1%), Ototoxicity (1%)
<1%
Asterixis, Dehydration, Hypotension, Orthostatic hypotension, Pruritus, Rash, Renal failure, Serious skin reactions (ie, Stevens-Johnson syndrome, toxic epidermal necrolysis), Vertigo, Vomiting
Potentially Fatal: Encephalopathy (in patients with preexisting liver disease).
Mechanism of Action
Bumetanide induces diuresis by inhibiting reabsorption of water and electrolytes (sodium and chloride) in the ascending loop of Henle and proximal renal tubule.